Parenteral iron use: Possible contribution to exceeding target hemoglobin in hemodialysis patients

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 3, 2009, Pages 623-629

  Ibrahim, Hassan N ^a,b   Foley, Robert N ^a,b   Zhang, Rui ^a   Gilbertson, David T ^a   Collins, Allan J ^a,b  

^a MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; HEMOGLOBIN; IRON DEXTRAN; FERRIC ION; FERRIC OXIDE, SACCHARATED;

ADULT; AFRICAN AMERICAN; AGED; ANEMIA; ARTICLE; CAUCASIAN; COHORT ANALYSIS; DIABETIC NEPHROPATHY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG RESPONSE; DRUG USE; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON STORAGE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICARE; OBSERVATIONAL STUDY; PREDICTION; PREVALENCE; RETROSPECTIVE STUDY; SEX DIFFERENCE; BLOOD; CHRONIC KIDNEY FAILURE; DRUG COMBINATION; GOVERNMENT; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY ANEMIA; MIDDLE AGED; PRACTICE GUIDELINE; RENAL REPLACEMENT THERAPY; RISK; RISK ASSESSMENT; TIME; TREATMENT OUTCOME; UNITED STATES;

AGED; ANEMIA, IRON-DEFICIENCY; CENTERS FOR MEDICARE AND MEDICAID SERVICES (U.S.); DRUG THERAPY, COMBINATION; FEMALE; FERRIC COMPOUNDS; HEMATINICS; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; IRON-DEXTRAN COMPLEX; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; ODDS RATIO; PRACTICE GUIDELINES AS TOPIC; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 66149136505     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03850808     Document Type: Article

References (33)

1. Goodnough LT, Monk TG, Andriole GL: Erythropoietin therapy. N Engl J Med 336: 933-938, 1997
2. Jones M, Ibels L, Schenkel B, Zagari M: Impact of epoetin alfa on clinical end points in patients with chronic renal failure: A meta-analysis. Kidney Int 65: 757-767, 2004 (Pubitemid 38251052)
3. Ross SD, Fahrbach K, Frame D, Scheye R, Connelly JE, Glaspy J: The effect of anemia treatment on selected health-related quality-of-life domains: A systematic review. Clin Ther 25: 1786 - 1805, 2003
4. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006 (Pubitemid 44749317)
5. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006 (Pubitemid 44749316)
6. Thamer M, Zhang Y, Kaufman J, Cotter D, Dong F, Hernan MA: Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA 297: 1667-1674, 2007 (Pubitemid 46631625)
7. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 23: 5960-5972, 2005 (Pubitemid 46300213)
8. Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, Szechtman B, Roa W, Mulroy L, Rudinskas L, Gagnon B, Okawara GS, Levine MN: Randomized, double-blind, placebo-controlled trial of erythropoietin in non- small-cell lung cancer with disease-related anemia. J Clin Oncol 25: 1027-1032, 2007 (Pubitemid 46596751)
9. Khuri FR: Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med 356: 2445-2448, 2007 (Pubitemid 46919767)
10. Horl WH: Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol 18: 382-393, 2007
11. Aronoff GR: Safety of intravenous iron in clinical practice: implications for anemia management protocols. J Am Soc Nephrol 15: S99-S106, 2004 [suppl]
12. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: Update 2000. Am J Kidney Dis 37: S182-S238, 2001 [suppl 1]
13. Besarab A: Resolving the paradigm crisis in intravenous iron and erythropoietin management. Kidney Int Suppl S13-S18, 2006
14. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG: Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 16: 3070-3080, 2005 (Pubitemid 44743505)
15. Centers for Medicaid & Medicare Services: Clinical Performance Measures (CPM) Project. www.cms.hhs.gov/CPM-Project. Accessed September 8, 2008
16. Brewster UC, Coca SG, Reilly RF, Perazella MA: Effect of intravenous iron on haemodialysis catheter microbial colonization and blood-borne infection. Nephrology (Carlton) 10: 124-128, 2005
17. Agarwal R: Nonhematological benefits of iron. Am J Nephrol 27: 565-571, 2007
18. Reis KA, Guz G, Ozdemir H, Erten Y, Atalay V, Bicik Z, Ozkurt ZN, Bali M, Sindel S: Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease. Int Heart J 46: 255-264, 2005
19. Drueke TB, Massy ZA: Intravenous iron: How much is too much? J Am Soc Nephrol 16: 2833-2835, 2005 (Pubitemid 44743479)
20. de Vecchi AF, Novembrino C, Lonati S, Ippolito S, Bamonti F: Two different modalities of iron gluconate i.v. administration: Effects on iron, oxidative and inflammatory status in peritoneal dialysis patients. Nephrol Dial Transplant 22: 1709-1713, 2007 (Pubitemid 47073773)
21. Zager RA, Johnson AC, Hanson SY, Wasse H: Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 40: 90-103, 2002
22. Sengoelge G, Kletzmayr J, Ferrara I, Perschl A, Horl WH, Sunder-Plassmann G: Impairment of transendothelial leukocyte migration by iron complexes. J Am Soc Nephrol 14: 2639-2644, 2003 (Pubitemid 37169351)
23. Deicher R, Ziai F, Cohen G, Mullner M, Horl WH: Highdose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int 64: 728-736, 2003 (Pubitemid 36871948)
24. Zager RA, Johnson AC, Hanson SY: Parenteral iron therapy exacerbates experimental sepsis. Kidney Int 65: 2108-2112, 2004
25. Lim CS, Vaziri ND: The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure. Kidney Int 65: 1802-1809, 2004
26. Michelis R, Gery R, Sela S, Shurtz-Swirski R, Grinberg N, Snitkovski T, Shasha SM, Kristal B: Carbonyl stress induced by intravenous iron during haemodialysis. Nephrol Dial Transplant 18: 924-930, 2003 (Pubitemid 36592534)
27. Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106: 2212-2217, 2002 (Pubitemid 35222215)
28. Feldman HI, Joffe M, Robinson B, Knauss J, Cizman B, Guo W, Franklin-Becker E, Faich G: Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 15: 1623-1632, 2004 (Pubitemid 38679688)
29. Sullivan JL: Stored iron and vascular reactivity. Arterioscler Thromb Vasc Biol 25: 1532-1535, 2005
30. Sengoelge G, Sunder-Plassmann G, Horl WH: Potential risk for infection and atherosclerosis due to iron therapy. J Ren Nutr 15: 105-110, 2005 (Pubitemid 40093692)
31. Besarab A, Bolton K, Browne J, Egrie J, Nissenson A, Okamoto D, Schwab S, Goodkin D: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998 (Pubitemid 28385655)
32. Streja E, Kovesdy CP, Greenland S, Kopple JD, McAllister CJ, Nissenson AR, Kalantar-Zadeh K: Erythropoietin, iron depletion, and relative thrombocytosis: A possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 52: 727-736, 2008
33. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, Zazra JJ, Anandan JV, Gupta A: Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11: 530-538, 2000 (Pubitemid 30115083)